{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-12479"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-12479","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"Overcoming Microenvironmentally Mediated Resistance in Targetable Non-Small Cell Lung Cancer","abstract":"The introduction of targeted therapies has resulted in immense success in treating lung cancer patients, where many patients experience long-term remission. Yet, the tumors relapse into an advanced state of disease, and ultimately, treatment failure. This can be ascribed to incomplete eradication of tumor cells by targeted therapies, which enables the residual tumor cells to propagate resistant tumors and cause subsequent relapse in patients. Therapy sensitivity is influenced not only by cell-intrinsic mechanisms but also by inputs from the stromal microenvironment. Despite widespread recognition of the stromal microenvironment's role in modulating therapy sensitivity, its contribution to therapeutic responses in vivo remains insufficiently characterized. Here, we investigated the contribution of stroma-mediated resistance in xenograft models of ALK+ NSCLC against ALK-targeted therapies. We report that proximity to the stroma partially protects the tumor cells against ALK-targeted therapy. This protective effect is evident during both remission and relapse, indicating the importance of stroma-mediated resistance in both persistence of tumor cells and in therapeutic resistance. Our study reports that spatial aspects of stromal-mediated resistance effects, such as stromal abundance and dispersal, can influence the responses to the therapy. From a molecular mechanistic perspective, the protective effect of the stromal niche involves multiple mechanisms, including growth factors and extracellular matrix components, resulting in multifactorial effects that protect the tumor cells from therapy. Consequently, targeting individual resistance mechanisms can improve responses to targeted therapy but is insufficient to counteract the protective effects of stroma. Using both in vitro and in vivo validation experiments, we demonstrated that targeting shared collateral sensitivities of therapy-persister cells represents a more effective therapeutic approach. Together, our findings suggest that stroma-mediated resistance significantly contributes to both residual and progressive disease, underscoring limitations of strategies that target single resistance mechanisms. Our studies emphasize the need for a broader approach that considers the multifactorial nature of therapy resistance in overcoming therapy resistance.","abstract_html":"The introduction of targeted therapies has resulted in immense success in treating lung cancer patients, where many patients experience long-term remission. Yet, the tumors relapse into an advanced state of disease, and ultimately, treatment failure. This can be ascribed to incomplete eradication of tumor cells by targeted therapies, which enables the residual tumor cells to propagate resistant tumors and cause subsequent relapse in patients. Therapy sensitivity is influenced not only by cell-intrinsic mechanisms but also by inputs from the stromal microenvironment. Despite widespread recognition of the stromal microenvironment&#x27;s role in modulating therapy sensitivity, its contribution to therapeutic responses in vivo remains insufficiently characterized. Here, we investigated the contribution of stroma-mediated resistance in xenograft models of ALK+ NSCLC against ALK-targeted therapies. We report that proximity to the stroma partially protects the tumor cells against ALK-targeted therapy. This protective effect is evident during both remission and relapse, indicating the importance of stroma-mediated resistance in both persistence of tumor cells and in therapeutic resistance. Our study reports that spatial aspects of stromal-mediated resistance effects, such as stromal abundance and dispersal, can influence the responses to the therapy. From a molecular mechanistic perspective, the protective effect of the stromal niche involves multiple mechanisms, including growth factors and extracellular matrix components, resulting in multifactorial effects that protect the tumor cells from therapy. Consequently, targeting individual resistance mechanisms can improve responses to targeted therapy but is insufficient to counteract the protective effects of stroma. Using both in vitro and in vivo validation experiments, we demonstrated that targeting shared collateral sensitivities of therapy-persister cells represents a more effective therapeutic approach. Together, our findings suggest that stroma-mediated resistance significantly contributes to both residual and progressive disease, underscoring limitations of strategies that target single resistance mechanisms. Our studies emphasize the need for a broader approach that considers the multifactorial nature of therapy resistance in overcoming therapy resistance.","abstract_has_math":false,"creators":["Desai, Bina"],"institution":"University of South Florida","degree_name":"Doctor of Philosophy (Ph.D.)","degree_level":"Dissertation","degree_discipline":"Molecular Biosciences","degree_department":null,"school":null,"contributors":["Andriy Marusyk, Ph.D.","Eric Lau, Ph.D.","Karen Mann, Ph.D.","David Basanta, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-08-29T07:00:00Z","date_published":"2024-08-29T07:00:00Z","updated_at":"2026-11-19T08:51:46Z","subjects":["ALK+","KRASG12C","Lung cancer","Stromal resistance","Targeted therapies","Biology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/11176","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/11176","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-12479","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Andriy Marusyk, Ph.D.","Eric Lau, Ph.D.","Karen Mann, Ph.D.","David Basanta, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Desai, Bina"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2024-08-29T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Molecular Biosciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation","Ph.D."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (Ph.D.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["ALK+","KRASG12C","Lung cancer","Stromal resistance","Targeted therapies","Biology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/11176"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The introduction of targeted therapies has resulted in immense success in treating lung cancer patients, where many patients experience long-term remission. Yet, the tumors relapse into an advanced state of disease, and ultimately, treatment failure. This can be ascribed to incomplete eradication of tumor cells by targeted therapies, which enables the residual tumor cells to propagate resistant tumors and cause subsequent relapse in patients. Therapy sensitivity is influenced not only by cell-intrinsic mechanisms but also by inputs from the stromal microenvironment. Despite widespread recognition of the stromal microenvironment's role in modulating therapy sensitivity, its contribution to therapeutic responses in vivo remains insufficiently characterized. Here, we investigated the contribution of stroma-mediated resistance in xenograft models of ALK+ NSCLC against ALK-targeted therapies. We report that proximity to the stroma partially protects the tumor cells against ALK-targeted therapy. This protective effect is evident during both remission and relapse, indicating the importance of stroma-mediated resistance in both persistence of tumor cells and in therapeutic resistance. Our study reports that spatial aspects of stromal-mediated resistance effects, such as stromal abundance and dispersal, can influence the responses to the therapy. From a molecular mechanistic perspective, the protective effect of the stromal niche involves multiple mechanisms, including growth factors and extracellular matrix components, resulting in multifactorial effects that protect the tumor cells from therapy. Consequently, targeting individual resistance mechanisms can improve responses to targeted therapy but is insufficient to counteract the protective effects of stroma. Using both in vitro and in vivo validation experiments, we demonstrated that targeting shared collateral sensitivities of therapy-persister cells represents a more effective therapeutic approach. Together, our findings suggest that stroma-mediated resistance significantly contributes to both residual and progressive disease, underscoring limitations of strategies that target single resistance mechanisms. Our studies emphasize the need for a broader approach that considers the multifactorial nature of therapy resistance in overcoming therapy resistance."]},{"key":"dc:title","label":"Title","values":["Overcoming Microenvironmentally Mediated Resistance in Targetable Non-Small Cell Lung Cancer"]}]}],"canonical_facts":{"dc:contributor":["Andriy Marusyk, Ph.D.","Eric Lau, Ph.D.","Karen Mann, Ph.D.","David Basanta, Ph.D."],"dc:creator":["Desai, Bina"],"dc:date":["2024-08-29T07:00:00Z"],"dc:description":["The introduction of targeted therapies has resulted in immense success in treating lung cancer patients, where many patients experience long-term remission. Yet, the tumors relapse into an advanced state of disease, and ultimately, treatment failure. This can be ascribed to incomplete eradication of tumor cells by targeted therapies, which enables the residual tumor cells to propagate resistant tumors and cause subsequent relapse in patients. Therapy sensitivity is influenced not only by cell-intrinsic mechanisms but also by inputs from the stromal microenvironment. Despite widespread recognition of the stromal microenvironment's role in modulating therapy sensitivity, its contribution to therapeutic responses in vivo remains insufficiently characterized. Here, we investigated the contribution of stroma-mediated resistance in xenograft models of ALK+ NSCLC against ALK-targeted therapies. We report that proximity to the stroma partially protects the tumor cells against ALK-targeted therapy. This protective effect is evident during both remission and relapse, indicating the importance of stroma-mediated resistance in both persistence of tumor cells and in therapeutic resistance. Our study reports that spatial aspects of stromal-mediated resistance effects, such as stromal abundance and dispersal, can influence the responses to the therapy. From a molecular mechanistic perspective, the protective effect of the stromal niche involves multiple mechanisms, including growth factors and extracellular matrix components, resulting in multifactorial effects that protect the tumor cells from therapy. Consequently, targeting individual resistance mechanisms can improve responses to targeted therapy but is insufficient to counteract the protective effects of stroma. Using both in vitro and in vivo validation experiments, we demonstrated that targeting shared collateral sensitivities of therapy-persister cells represents a more effective therapeutic approach. Together, our findings suggest that stroma-mediated resistance significantly contributes to both residual and progressive disease, underscoring limitations of strategies that target single resistance mechanisms. Our studies emphasize the need for a broader approach that considers the multifactorial nature of therapy resistance in overcoming therapy resistance."],"dc:identifier":["https://digitalcommons.usf.edu/etd/11176"],"dc:subject":["ALK+","KRASG12C","Lung cancer","Stromal resistance","Targeted therapies","Biology"],"dc:title":["Overcoming Microenvironmentally Mediated Resistance in Targetable Non-Small Cell Lung Cancer"],"thesis:degree_discipline":["Molecular Biosciences"],"thesis:degree_level":["Dissertation","Ph.D."],"thesis:degree_name":["Doctor of Philosophy (Ph.D.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:51:46Z"}